The disclosure is directed to an oral formulation and dosage form of ruxolitinib, or a pharmaceutically acceptable salt thereof; which are useful in the treatment of Janus kinase (JAK) associated diseases.

In some aspects, the disclosure relates to compositions and methods comprising ActRII polypeptides to treat, prevent, or reduce the progression rate and/or severity of pulmonary arterial hypertension, particularly treating, preventing or reducing the progression rate and/or severity of one or more pulmonary arterial hypertension associated complications.

The present invention relates to a process for preparing a solid composition comprising at least one active ingredient and at least one excipient comprising: i) mixing said at least one active ingredient and said at least one excipient in a granulator to obtain wet granules; ii) spreading wet granules on a tray and let stand for 2 to 24 hours between 15 and 25° C.; iii) compressing granules obtained after step ii) with a tablet press; and iv) collecting the solid composition. The invention further relates a solid composition obtained by such process.

Non-naturally occurring microorganisms are provided that produce C40 carotenoid compound(s), utilizing exogenously added enzyme activities. Methods of producing C40 carotenoid compounds in microbial cultures, and feed and nutritional supplement compositions that include the C40 carotenoid compounds produced in the microbial cultures, are also provided.

Disclosed is a dry powder oral formulation that includes an active pharmaceutical ingredient (API), a lecithin powder, a galactomannan, one or more sweetening agents, one or more flavoring agents and an organic acid in a pharmaceutically acceptable preparation. Also disclosed are an excipient composition in absence of an API and methods of making and using the formulations and compositions. Also disclosed is a chewable, swallowable, and/or orally disintegrating tablet comprising an API, a lecithin powder, a galactomannan, one or more sweetening agents, one or more flavoring agents and an organic acid in a pharmaceutically acceptable preparation.

The disclosure relates to compositions containing allyl isothiocyanate and methods of use thereof for stimulating tearing in a subject to treat dry eye.

Disclosed is a method for treating ear disorders, including the administration of (+)-azasetron, or a pharmaceutically acceptable salt and/or solvate thereof.

The invention provides a composition and method for treating prostate disorders. The composition can be formulated to provide a saw palmetto oil having about 3% w/w β-sitosterol.

The invention provides a composition and method for treating prostate disorders. The composition can be formulated to provide a saw palmetto oil having about 3% w/w β-sitosterol.

Films (ODFs) that include botanical extract are provided, as well as methods of making and using the same.